


Doravirine

Cat. No.:	HY-16767		
CAS No.:	1338225-97-0		
Molecular Formula:	C ₁₇ H ₁₁ ClF ₃ N ₅ O ₃		
Molecular Weight:	425.75		
Target:	HIV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



Solubility: DMSO: ≥ 30 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

PREPARING STOCK SOLUTIONS

Volume Concentration	Mass	1 mg	5 mg	10 mg
		1 mM	2.3488 mL	11.7440 mL
5 mM	0.4698 mL	2.3488 mL	4.6976 mL	
10 mM	0.2349 mL	1.1744 mL	2.3488 mL	

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Doravirine is a novel non-nucleoside inhibitor of HIV-1 reverse transcriptase with potent activity against wild-type virus (95% inhibitory concentration 19 nM, 50% human serum). target:HIV [1]In vitro: Doravirine exhibits potent antiviral activity against wild-type virus and K103N, Y181C, and K103N/Y181C mutant viruses, with IC₅₀ value of 12, 21, 31, and 33 nM, respectively. [1] MK-1439 exhibited similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses).[2]In vivo: Administration of 50 mg doravirine with a high-fat meal is associated with slight elevations in AUC time zero to infinity (AUC_{0-∞}) and C₂₄ h with no change in C_{max}. Midazolam AUC_{0-∞} is slightly reduced by coadministration of doravirine (geometric mean ratio 0.82, 90% CI 0.70, 0.97). [3]

REFERENCES

- [1]. Feng M et al. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. *Antimicrob Agents Chemother.* 2016 Mar 25;60(4):2241-7.
- [2]. Lai MT et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. *Antimicrob Agents Chemother.*

2014;58(3):1652-63.

[3]. Anderson MS et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. *Antivir Ther.* 2015;20(4):397-405.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA